Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)

Summary

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, ascending dose, dose ranging study to evaluate up to three doses of R935788 (50 mg bid, 100 mg bid and 150 mg bid). Approximately 180 patients who have had rheumatoid arthritis for a minimum of 12 months and who have been receiving a weekly methotrexate (MTX) dose for a minimum of 6 months will be enrolled into the study.

Timeline

Start

2006-08

Primary completion

2007-10

Completion

2007-12

Drugs

Indications